Multi-center, Double-blind, Randomized, Placebo-controlled Study of Selective 11 Beta-HSD1 Inhibition With RO5093151 for 12 Weeks to Investigate Efficacy, Safety and Pharmacokinetics of RO5093151 in Non-alcoholic Fatty Liver Disease and Its Metabolic Consequences.
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009026/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This multi-center, double-blind, randomized, placebo-controlled study will evaluate the
change in liver fat content, pharmacokinetics and safety of RO5093151 in patients with
non-alcoholic fatty liver disease. Patients will be randomized to receive either daily oral
doses of RO5093151 or matching placebo. The anticipated time on study treatment is 12 weeks.
提供机构：
Vivli
创建时间：
2023-06-20
